Frequency of the off-label use of monoclonal antibodies in clinical practice: A systematic review of the literature

Current Medical Research and Opinion

Volumn 30, Issue 3, 2014, Pages 471-480

  Zarkali, Angeliki ^a   Karageorgopoulos, Drosos E ^a,b,c   Rafailidis, Petros I ^a,d   Falagas, Matthew E ^a,d,e  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HYGEIA HOSPITAL   (Greece)

^c Hellenic Center of Disease Control and Prevention   (Greece)

^d HENRY DUNANT HOSPITAL   (Greece)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug prescriptions; Monoclonal antibodies; Off label use; Unapproved use; Unlicensed use

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; BEVACIZUMAB; CETUXIMAB; GEMTUZUMAB; IBRITUMOMAB TIUXETAN; INFLIXIMAB; MONOCLONAL ANTIBODY; OMALIZUMAB; PALIVIZUMAB; RANIBIZUMAB; RITUXIMAB; TOSITUMOMAB; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTHROPATHY; ASTHMA; AUTOIMMUNE HEMOLYTIC ANEMIA; BREAST CANCER; CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; CYSTIC FIBROSIS; DRUG COST; DRUG INDICATION; FOOD AND DRUG ADMINISTRATION; GRAFT VERSUS HOST REACTION; HAIRY CELL LEUKEMIA; HISTIOCYTOSIS; HODGKIN DISEASE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LICHEN (DISEASE); MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; METASTATIC COLORECTAL CANCER; MONOTHERAPY; NONHODGKIN LYMPHOMA; OFF LABEL DRUG USE; PITYRIASIS; PRESCRIPTION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SARCOIDOSIS; SCLERODERMA; SYSTEMATIC REVIEW; T CELL LYMPHOMA; ULCERATIVE COLITIS; WALDENSTROEM MACROGLOBULINEMIA; NEOPLASMS;

ANTIBODIES, MONOCLONAL; HUMANS; NEOPLASMS;

EID: 84896715525     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.855186     Document Type: Review

References (33)

1. Hooks MA, Wade CS, Millikan Jr WJ, Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy 1991;11:26-37
2. Nightingale SL. Off-label use of prescription drugs. Am Fam Physician 2003;68:425-7
3. Ekins-Daukes S, Helms PJ, Taylor MW, et al. Off-label prescribing to children: attitudes and experience of general practitioners. Br J Clin Pharmacol 2005;60:145-9
4. Mellor JD, Bensted KE, Chan PL. Off label and unlicensed prescribing in a specialist oncology center in Australia. Asia-Pac J Clin Oncol 2009;5:242-6
5. Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr 2005;164:552-8
6. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among officebased physicians. Arch Intern Med 2006;166:1021-6
7. Roila F, Ballatori E, Labianca R, De Braud F. Off-label prescription of antineoplastic drugs: an Italian prospective, observational, multicenter survey. Tumori 2009;95:647-51
8. Van den Berg H, Tak N. Licensing and labelling of drugs in a paediatric oncology ward. Br J Clin Pharmacol 2011;72:474-81
9. Butterly SJ, Pillans P, Horn B. Off-label use of rituximab in a tertiary Queensland hospital. Intern Med J 2010;40:443-52
10. Díaz-Lagares C, Pérez-Alvarez R, García- Hernández FJ. Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Res Ther 2011;13:R112
11. Kruse GB, Amonkar MM, Smith G. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population. J Manag Care Pharm 2008;14:844-57
12. Van Allen EM, Miyake T, Gunn N. Off-label use of rituximab in a multipayer insurance system. J Oncol Pract 2011;7:76-9
13. Conde García MC, Fernandez Feijoo MA, Calleja Hernandez MA. [Study of rituximab efficacy, cost, safety, and compliance of its package leaflet in a tertiary hospital]. Farm Hosp 2009;33:305-11
14. Kocs D, Fendrick AM. Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience. Am J Manag Care 2003;9:393-400; quiz 401-2
15. Gray SW, Armstrong K, Demichele A. Colon cancer patient information seeking and the adoption of targeted therapy for on-label and off-label indications. Cancer 2009;115:1424-34
16. Bonifazi M, Rossi M, Moja L. Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety. Oncologist 2012;17:117-24
17. Brechner RJ, Rosenfeld PJ, Babish JD. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol 2011;151:887-95 e1
18. Pearson SA, Ringland CL, Ward RL. Trastuzumab and metastatic breast cancer: trastuzumab use in Australia-monitoring the effect of an expensive medicine access program. J Clin Oncol 2007;25:3688-93
19. Freeman CP, Leonard CE, de Nava KL. Utilization of anticancer biologic products among Medicare beneficiaries, by Diagnostic Cancer Subchapter, 2006-2009: Data Points #7. Data Points Publication Series [Internet]. 2011
20. Carmona L, Descalzo MA, Ruiz-Montesinos D. Safety and retention rate of offlabel uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. Rheumatology (Oxford) 2011;50:85-92
21. Plard C, Serry G, Faure P. [Assessment of "Contrat de bon usage" on 4 years period: conformity to guidelines-experience of anti-tnfalpha]. Therapie 2008;63:281-9
22. Ljung T, Karlén P, Schmidt D. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004;53:849-53
23. Turner A, Begg C, Smith B. The influence over a period of 8 years of patterns of prescribing palivizumab for patients with and without congenitally malformed hearts, and in admissions to paediatric intensive care. Cardiol Young 2009;19:346-51
24. Speer ME, Fernandes CJ, Boron M. Use of Palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis. Pediatr Infect Dis J 2008;27:559-61
25. Broder MS, Zazzali JL, Chang E. Concomitant asthma medication use by patients receiving omalizumab 2003-2008. J Asthma 2011;48:1058-62
26. Savonitto S, Ambrosini V, Marzocchi A. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study. Ital Heart J 2005;6:106-18
27. Alasfoor K, Alrasheed M, Alsayegh F. Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP). Ann Hematol 2009;88:239-43
28. Li Z, Mou W, Lu G, Cao J. Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia. Int J Hematol 2011;93:91-8
29. Mueller BU, Bennett CM, Feldman HA. One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. Pediatr Blood Cancer 2009;52:259-62
30. Zaja F, Vianelli N, Volpetti S. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol 2010;85:329-34
31. Fong DS, Custis P, Howes J. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study. Ophthalmology 2010;117:298-302
32. Raftery J, Clegg A, Jones J. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 2007;91:1244-6
33. Rafailidis PI, Kakisi OK, Vardakas K. Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer 2007;109:2182-9